Proteome Sciences Share Discussion Threads

[colinhy] 11/9/2023 08:53

11 September 2023,International Joournal of Molecular Sciences

Simufilam Reverses Aberrant Receptor Interactions of Filamin A in Alzheimer’s Disease

Conclusions
FLNA, in an altered conformation, is a deviant receptor-associated protein critical to AD pathology. Simufilam’s disruption of the aberrant FLNA linkage to α7nAChR reduces Aβ42’s binding to and pathogenic signaling via this receptor, thereby restoring healthy α7nAChR neurotransmission. Simufilam’s disruption of deviant FLNA linkages to multiple inflammatory receptors suppresses neuroinflammation induced by these receptors. The dissociation of FLNA from all these receptors is coincident with simufilam’s reversal of an altered conformation of FLNA, as indicated by isoelectric focusing points. It is not surprising that an altered conformation, inducible by soluble Aβ42, would lead to aberrant protein interactions. Alternatively, Aβ42-induced aberrant protein interactions could induce the altered conformation.
By binding a single protein target, simufilam reduces a predominant neurodegeneration pathway and multiple neuroinflammatory signaling pathways of soluble amyloid and potentially other inflammatory ligands in AD. A multi-pronged therapeutic approach, whether by agents with multiple mechanisms or by drug combinations, may be necessary to treat this devastating disease.


================================

A blood based diagnostic assay for Alzheimer's disease (SAVADx) developed by Cassava Sciences working with Proteome Sciences for use in diagnosis of Simufilam and patented by both Cassava and Proteome Sciences

[colinhy] 08/9/2023 20:12

Working with third parties, we are evaluating the use of mass spectrometry to detect FLNA without the use of antibodies.

==========================

[colinhy] 08/9/2023 18:32

From links below Proteome Sciences and Cassava Sciences (previously Pain Therapeutics) are both working on this diagnostic blood test for Alzheimer’s disease dementia and pituitary tumor.
============================
Pharmaceutical Technology August 28 2023

Simufilam hydrochloride by Cassava Sciences for Alzheimer’s Disease: Likelihood of Approval



BLOOD-BASED DIAGNOSTIC ASSAYS FOR ALZHEIMER'S DISEASE

United States Patent and Trademark Office Publication May 11 2023

[peverill] 08/9/2023 13:00

He was though,when do I get out of jail???? Tia.

[stocktastic] 07/9/2023 21:53

"There is also a new CK1d therapeutic for Alzheimer's disease patent family currently being granted to Proteome Sciences"

Any companies showing any interest in CK1d?

Patent is just an expensive piece of paper otherwise

[small crow] 07/9/2023 02:24

Feel free to bench-press ...

[elpirata] 06/9/2023 18:43

dont forget the porky pies too

[elpirata] 04/9/2023 13:01

that may be the case wasjobber but you certainly cant fault jt for effort, as futile and 100% wrong as it was

[wasjobber] 04/9/2023 12:50

As Proteome Sciences have recently said, "when they float on the New York stock exchange, it will attract far more informed knowledgeable investors, who understand the technology better and it will provide a much higher valuation for the company"

[elpirata] 04/9/2023 12:21

the avatar formerly known as jt?

purple or yellow rain?

Lest we forget;

jt 27 Mar '11 - 06:11 - 11 of 92544
0 0 0
PROTEOME SCIENCES: A MONEY MAKING MACHINE. (DESCRIBES THE COMMERCIAL USEFULLNESS OF PROTEOME'S 9 PANEL BLOOD BIOMARKER ASSAY FOR ALZHEIMER'S DISEASE DETECTION AND MONITORING)

...So back to the figures: As already stated, the testing per sample is not cheap and “comfortably into the hundreds”. An Alzheimer’s disease trial typically needs 1200 to 2400 patients studied over two years and there are currently about 300 Alzheimer’s trials on-going at the present time. A patient in this time is evaluated between 3 and 6 times. It’s over to you Goatherd, although it does not take maths genius to value the annual revenue per trial based on the mean figures as in the region of one and a half million pounds, dollars, Euros, take your pick.

Mean patients: 1800 X mean number of tests per year 2.25 X cost per test 400 pounds sterling.
Total =Upwards of one and a half million per trial per annum.
10 trials 15 million per annum
20 trials 30 million per annum
Millipore (exclusive) License Up front, say ? mln
Millipore (exclusive) Revenue (royalty) say ? mln per annum.
Uplift from EMA accreditation of the Validation study in reappraising all biomarkers contracts ? mln
TMT per annum ?
Thermo Fisher ?
Stroke deal. ?
GSK AD deal ?
(?) Shareholders to add their own figures

How about £0

[pools2] 04/9/2023 08:30

wasjobber,

There is also a new CK1d therapeutic for Alzheimer's disease patent family currently being granted to Proteome Sciences.

Yes I agree, events could get very interesting.

[wasjobber] 03/9/2023 23:38

pools2, in my opinion, it has always been about Alzheimer's Disease for Proteome Sciences. That is where they have opportunity to make really big returns for investors. Their AD portfolio has received very little investor attention of late, but it forms a significant part of their patent estate. With new AD patents now being granted and huge interest from industry players now keen to use blood biomarkers, we could (at long last) see some very lucrative licensing deals. BUY.

[pools2] 03/9/2023 19:05

Please note:

There are several very interesting new patent family applications currently being granted to Proteome Sciences for Alzheimer's and other neurodegenerative conditions.

[mashman] 31/8/2023 22:54

On the brighter side, prm gave me my first ever £10K day trade :-)

[mashman] 31/8/2023 22:48

This technology is so outdated and the prm old fudgies will not be moved from their aged beliefs.

AI will completely take over and antique pharma like CP's will have to adapt or disappear.

PRM do not have the cash or wherewithal to proceed and Pierce will bleed it dry.

IMO as a 20+ year watcher

[dominiccummings] 31/8/2023 21:21

Listen... once that Mad Cow disease stuff is completed this is going to fly!

[base7] 30/8/2023 17:36

That would be a great reason for an Investor meets on 19/9